| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
This compound does not possess a specific biological target; its primary function is as a chemical building block for peptide synthesis. The Boc group provides acid-labile protection for the amino group, while the benzyl ester provides hydrogenolysis-labile protection for the carboxyl group. This orthogonal protection strategy allows for selective deprotection, making it a versatile intermediate in peptide synthesis. Amino acid derivatives like this one have been commercially used as ergogenic supplements.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
This compound is not a biological agent and does not exhibit direct in vitro biological activity in a pharmacological sense. Its value lies in its chemical utility as a protected amino acid building block. Amino acids and their derivatives have been commercially used as ergogenic supplements, influencing the release of anabolic hormones, the availability of fuel for activity, and the prevention of muscular damage. However, any biological activity would reside in the final deprotected product. |
| ln Vivo |
Boc-L-alanine benzyl ester is not administered in vivo as a therapeutic agent. It is a research chemical utilized as a building block in peptide synthesis. The final deprotected peptide product, not this protected intermediate, would be the subject of in vivo pharmacological testing. The compound is for research use only and is not intended for human or veterinary therapeutic applications.
|
| Enzyme Assay |
Non-cellular enzyme/receptor binding assays are not applicable to Boc-L-alanine benzyl ester as it is not biologically active. Its use is in organic synthesis and peptide chemistry. A typical protocol involves its use as a building block in peptide synthesis, where the Boc group can be removed under acidic conditions (e.g., TFA) and the benzyl ester can be removed by hydrogenolysis (H2/Pd-C) to reveal the free amino and carboxyl groups for further coupling.
|
| Cell Assay |
This compound is not used in cell-based assays as a therapeutic agent. Its applications are in synthetic chemistry and peptide synthesis. It should be stored as a powder at -20°C for up to 3 years or at 4°C for up to 2 years; in solvent, it can be stored at -80°C for 6 months or at -20°C for 1 month. It has a density of 1.1±0.1 g/cm3 and a boiling point of 392.7±25.0°C. The product is for research purposes only.
|
| Animal Protocol |
In vivo animal experiments do not involve Boc-L-alanine benzyl ester as a test article. It is a chemical intermediate used in the synthesis of peptide-based drug candidates. If a researcher synthesizes a therapeutic peptide using this building block, that final deprotected and purified peptide product would be subjected to animal testing. The protected amino acid itself is never administered to animals as a test compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to Boc-L-alanine benzyl ester as it is not a drug. It is a small molecule (MW 279.33 g/mol) with the formula C15H21NO4. Its computed XLogP3-AA is 2.7. These properties are relevant for chemical handling and storage rather than for systemic exposure studies. The compound is not designed to be bioavailable, as the protecting groups are intended to be removed during peptide synthesis.
|
| Toxicity/Toxicokinetics |
The toxicity of Boc-L-alanine benzyl ester is not extensively documented, as it is a research chemical not intended for human or veterinary use. As with all Boc-protected amino acids, standard laboratory safety precautions should be followed, including handling in a well-ventilated area with appropriate personal protective equipment. It should be stored at -20°C or 4°C and protected from moisture. It is not intended for diagnostic, therapeutic, or other medical applications.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
Boc-L-alanine benzyl ester (N-tert-butoxycarbonyl-L-alanine benzyl ester) is an orthogonally protected L-alanine derivative featuring a Boc group on the α-amino terminus and a benzyl ester on the carboxyl terminus. The orthogonal protection strategy allows for selective deprotection, making it a versatile intermediate in peptide synthesis. This compound is a valuable organic compound for life science research. It is not a pharmaceutical and has no clinical trials or approved therapeutic status.
|
| Molecular Formula |
C15H21NO4
|
|---|---|
| Molecular Weight |
279.33
|
| Exact Mass |
279.147
|
| CAS # |
51814-54-1
|
| PubChem CID |
10972741
|
| Appearance |
Colorless to off-white <25.5°C solid powder,>26°C liquid
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
392.7±25.0 °C at 760 mmHg
|
| Melting Point |
25.5-26℃ (ligroine )
|
| Flash Point |
191.3±23.2 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.505
|
| LogP |
3.41
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
20
|
| Complexity |
329
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@@H](C(=O)OCC1=CC=CC=C1)NC(=O)OC(C)(C)C
|
| InChi Key |
KZNCFIIFMFCSHL-NSHDSACASA-N
|
| InChi Code |
InChI=1S/C15H21NO4/c1-11(16-14(18)20-15(2,3)4)13(17)19-10-12-8-6-5-7-9-12/h5-9,11H,10H2,1-4H3,(H,16,18)/t11-/m0/s1
|
| Chemical Name |
benzyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5800 mL | 17.9000 mL | 35.7999 mL | |
| 5 mM | 0.7160 mL | 3.5800 mL | 7.1600 mL | |
| 10 mM | 0.3580 mL | 1.7900 mL | 3.5800 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
